Eco Animal Health Group diversifying its product portfolio

–News Direct–

ECO Animal Health Group PLC (AIM: EAH) CEO David Hallas speaks to Thomas Warner from Proactive about the company's recent performance and his hopes for its future, during his first interview on the platform. Hallas starts by giving an overview of the business, which specialises in developing, registering and marketing pharmaceutical products for global animal health markets and particularly for pigs and chickens.

The company's flagship product Aivlosin is a proprietary, patented medication which is effective against both respiratory and enteric diseases in pigs and poultry is an anti-infective treatment for respiratory and enteric diseases in animals. Over the past year, the company achieved 4% revenue growth, surpassing market expectations. Hallas highlighted strong growth in Latin America and South and Southeast Asia, driven by increasing demand for high-quality white meat.

Looking ahead, Eco Animal Health plans to diversify into preventative disease solutions, such as vaccines and monoclonal antibodies, targeting the US market by the end of next year. Hallas also addressed misconceptions, emphasising that the company's growth is not solely reliant on the Chinese market and that a balanced approach of prevention and treatment is essential for success.

Contact Details

Proactive UK Ltd

Proactive UK Ltd

+44 20 7989 0813

View source version on

Eco Animal Health Group PLC

comtex tracking


About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Daily Scotland News journalist was involved in the writing and production of this article.